Konica Minolta Precision Medicine Announces Changes to Executive Leadership Team

Aliso Viejo, CA., May 4, 2021 — Konica Minolta Precision Medicine, Inc. (KMPM) announced today changes to its executive leadership team effective immediately. The changes reflect a thoughtful and strategic approach to the next phase of growth and expansion for the global precision diagnostics organization.

Aaron Elliott, current CEO of Ambry Genetics, has been named Chief Executive Officer of KMPM. In his new role, Dr. Elliott will be responsible for driving execution across all KMPM business units, which include Ambry Genetics, Invicro, and KMPM-Japan. During his 13-year tenure at Ambry, Dr. Elliott also served as Chief Operating Officer and Chief Scientific Officer, and saw the company through many trailblazing milestones including numerous novel first to market diagnostic tests, the landmark BRCA gene patent case which opened up genetic testing in the United States and the acquisition by Konica Minolta.

(more…)

Konica Minolta Precision Medicine Collaborates with AWS to Create the Next Generation of Precision Diagnostics

Tokyo (March 10, 2021)Konica Minolta Precision Medicine, Inc. (KMPM), a Konica Minolta Group company, announced today a five-year collaboration with Amazon Web Services, Inc. (AWS). As the Preferred Cloud Provider for KMPM, AWS will support the build-out of the company’s LATTICETM initiative globally. LATTICETM is a groundbreaking integrated diagnostic data platform that combines genomics, pathology, and radiology data along with other critical information to uncover new, clinically relevant biomarkers and create the next generation of diagnostic tests. As part of this collaboration, Amazon has made a financial investment in KMPM.

(more…)

TauIQ launches in Invicro’s Core Lab alongside seminal publication in the Journal of Nuclear Medicine

 

BOSTON, MA, 01 February 2021 Invicro LLC, a Konica Minolta company announces that the paper, TauIQ – A canonical image-based algorithm to quantify tau PET scans, will be published in The Journal of Nuclear Medicine (JNM). In conjunction with this publication, Invicro has launched 21 CFR Part 11 compliant TauIQ services in its Core Lab as part of its expanded IQ-Analytics Platform, which includes AmyloidIQ and DaTIQ.

(more…)

Invicro Collaborates with Yale’s, Dr. David Rimm to Expand the Utility of Quanticell™ for Clinical Pathology Applications

 

BOSTON, MA March 9, 2020, Invicro LLC, a Konica Minolta Company announced it has entered into a strategic research partnership with industry leading pathologist, Dr. David Rimm, MD, PhD, at The Yale University School of Medicine to advance the development of Quanticell, Konica Minolta’s propriety tissue biomarker detection technology.

(more…)

Evolution Research Group and Invicro LLC partner to offer Clinical Research and Advanced Data Analysis and Management Services

 

NEW PROVIDENCE, N.J. and BOSTON, MA, November 18, 2019 — Today, Evolution Research Group (ERG) and Invicro LLC, a Konica Minolta Company announced a strategic partnership to offer biotech and pharma sponsors early to late phase clinical research trials, advanced data analysis and project management services.

(more…)